Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
2 March 2022 |
Main ID: |
EUCTR2013-004025-88-AT |
Date of registration:
|
21/02/2014 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Previously Untreated Patients with Haemophilia A
|
Scientific title:
|
Safety and Efficacy of turoctocog alfa pegol (N8-GP) in Previously Untreated Patients with Haemophilia A
An open-label single-arm multicentre non-controlled phase 3a trial investigating safety and efficacy of N8-GP in prophylaxis and treatment of bleeding episodes in previously untreated paediatric patients with severe haemophilia A - pathfinder™6 |
Date of first enrolment:
|
20/03/2014 |
Target sample size:
|
125 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004025-88 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: no Randomised: no Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Algeria
|
Australia
|
Austria
|
Bulgaria
|
Canada
|
European Union
|
France
|
Germany
|
Greece
|
Israel
|
Italy
|
Japan
|
Malaysia
|
Portugal
|
Romania
|
Spain
|
Taiwan
|
Thailand
|
United States
| | | | | |
Contacts
|
Name:
|
Global Clinical Registry (GCR,1452)
|
Address:
|
Novo Alle
2880
Bagsvaerd
Denmark |
Telephone:
|
|
Email:
|
clinicaltrials@novonordisk.com |
Affiliation:
|
Novo Nordisk A/S |
|
Name:
|
Global Clinical Registry (GCR,1452)
|
Address:
|
Novo Alle
2880
Bagsvaerd
Denmark |
Telephone:
|
|
Email:
|
clinicaltrials@novonordisk.com |
Affiliation:
|
Novo Nordisk A/S |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: - Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial - Male, age < 6 years at the time of signing informed consent - Diagnosis of severe haemophilia A (factor VIII activity level < 1%) based on medical records or central laboratory results - No prior use of purified clotting factor products (5 previous exposure to blood components is acceptable) Are the trial subjects under 18? yes Number of subjects for this age range: 125 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria: - Any history of FVIII inhibitor (defined by medical records) - Known or suspected hypersensitivity to trial product or related products - Previous participation in this trial. Participation is defined as administration of trial product - Receipt of any investigational medicinal product within 30 days before screening - Congenital or acquired coagulation disorder other than haemophilia A. Any chronic disorder or severe disease which, in the opinion of the Investigator, might jeopardise patient’s safety or compliance with the protocol. - Patient’s parent(s)/legally acceptable representative(s) mental incapacity, unwillingness to cooperate, or a language barrier precluding adequate understanding and cooperation
Age minimum:
Age maximum:
Gender:
Female: no Male: yes
|
Health Condition(s) or Problem(s) studied
|
Haemophilia A MedDRA version: 20.0
Level: LLT
Classification code 10018938
Term: Haemophilia A (Factor VIII)
System Organ Class: 100000004850
|
Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
|
Intervention(s)
|
Product Name: N8-GP rFVIII Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: TUROCTOCOG ALFA PEGOL Current Sponsor code: NNC129-1003 Concentration unit: U unit(s) Concentration type: equal Concentration number: 2000-
Product Name: N8-GP 500 U vial Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: TUROCTOCOG ALFA PEGOL Current Sponsor code: NNC129-1003 Concentration unit: U unit(s) Concentration type: equal Concentration number: 500-
|
Primary Outcome(s)
|
Timepoint(s) of evaluation of this end point: The primary endpoint will be evaluated when the first 50 PUPs have reached at least 50 exposure days and at end of trial. End of trial will be up to 4 years after the first patient has reached 100 exposure days
|
Secondary Objective: - To evaluate safety other than immunogenicity of N8-GP (turoctocog alfa pegol) in PUPs with severe haemophilia A - To evaluate efficacy of N8-GP (turoctocog alfa pegol) in PUPs with severe haemophilia A o in long-term prophylaxis treatment (bleeding preventive effect) o in the treatment of bleeding episodes
|
Primary end point(s): Incidence of FVIII inhibitors
|
Main Objective: To evaluate immunogenicity of N8-GP (turoctocog alfa pegol) in previously untreated patients (PUPs) with severe haemophilia A
|
Secondary Outcome(s)
|
Secondary end point(s): - Frequency of adverse events including serious adverse events and medical events of special interest. - Incidence of confirmed high titre inhibitors (defined as inhibitor titre > 5BU). - Number of breakthrough bleeding episodes during prophylaxis with N8-GP (annualised bleeding rate). - Haemostatic effect of N8-GP in treatment of bleeding episodes, assessed by a predefined 4-point haemostatic response scale "excellent", "good", "moderate" and "none").
|
Timepoint(s) of evaluation of this end point: The secondary endpoints will be evaluated when the first 50 PUPs have reached at least 50 exposure days and at end of trial. End of trial will be up to 4 years after the first patient has reached 100 exposure days.
|
Secondary ID(s)
|
NN7088-3908
|
2013-004025-88-DE
|
Source(s) of Monetary Support
|
Novo Nordisk A/S
|
Ethics review
|
Status: Approved
Approval date: 25/02/2014
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|